Hidragon Capital

Hidragon Capital does not publicly disclose its investment committee or fund managers. No principals are named on any available public records. This level of anonymity is consistent with a small number of Chinese private equity firms that operate with minimal external communications.

The firm focuses on early-stage venture, including seed, startup, and general venture rounds. It does not participate in growth-stage or late-stage deals. Its stage focus is narrower than many multi-stage private equity firms in China.

Based on available data, Hidragon Capital is structured as a private equity asset manager, not a single family office. It does not present itself as managing wealth for a specific family. Its fund structure is not disclosed, but the firm likely raises capital from institutional allocators and high-net-worth individuals.

The firm's disclosed strategy does not specify avoided sectors. However, its focus on early-stage technology and healthcare implies it does not invest in real estate, infrastructure, natural resources, or heavy manufacturing. No explicit negative screens have been published.

The source of capital—whether institutional, family-office, or high-net-worth—is not publicly disclosed. The firm's wealth origin is not published, making it difficult to assess LP concentration or any single-family influence.

The firm does not disclose its sourcing model. As a China-focused early-stage venture firm, it likely relies on a network of founders, angel investors, and co-investors in Shanghai's technology ecosystem. No public data on specific proprietary deal channels is available.

No parent entity, sibling fund, or affiliated operating company has been identified. The firm appears to operate as a standalone entity with no disclosed connections to larger financial groups or other asset managers. There is no public record of spinouts or predecessor firms.